EMEA-001493-PIP03-18
Key facts
| Invented name |
Xalkori
|
| Active substance |
crizotinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0399/2019
|
| PIP number |
EMEA-001493-PIP03-18
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|